Press Release - Ride the Pharma Wave with our Rights Issue
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare Ltd's rights issue at ₹1 per share in a 61:50 ratio has garnered a strong response, achieving 26.03% subscription by the end of Day 2. The issue price is significantly below the ₹1.85 closing price on May 2, 2025, making it attractive to existing shareholders. The renunciation window runs until May 9, 2025, with the issue closing on May 14, 2025. Proceeds will fund R&D expansion, working capital, CDMO (contract manufacturing) growth, and international market entry. The company recently secured a ₹182.7 crore multi-year export order from a UK-based pharmaceutical distributor in February 2025, covering anti-infective, cardiovascular, and CNS therapeutic segments.
The healthy Day-2 subscription signals positive shareholder confidence. With the issue priced at a deep discount to market, eligible shareholders gain a low-cost entry opportunity, though dilution is expected. Successful completion will strengthen the balance sheet and fund expansion into high-margin CDMO and global markets, supporting long-term growth.